## Benjamin B Gelman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12095216/publications.pdf Version: 2024-02-01

		87888	60623
111	7,247	38	81
papers	citations	h-index	g-index
111	111	111	5685
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A neuron-to-astrocyte Wnt5a signal governs astrogliosis during HIV-associated pain pathogenesis. Brain, 2022, 145, 4108-4123.	7.6	12
2	Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluid. Journal of NeuroVirology, 2022, 28, 281-290.	2.1	3
3	Acrolein and other toxicant exposures in relation to cardiovascular disease among marijuana and tobacco smokers in a longitudinal cohort of HIV-positive and negative adults. EClinicalMedicine, 2021, 31, 100697.	7.1	8
4	Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. Pain Medicine, 2021, 22, 1850-1856.	1.9	3
5	Novel Role for Macrophage Galactose-Type Lectin-1 to Regulate Innate Immunity against <i>Mycobacterium tuberculosis</i> . Journal of Immunology, 2021, 207, 221-233.	0.8	8
6	Advancing our understanding of HIV co-infections and neurological disease using the humanized mouse. Retrovirology, 2021, 18, 14.	2.0	8
7	Multimorbidity networks associated with frailty among middle-aged and older people with HIV. Aids, 2021, 35, 2451-2461.	2.2	14
8	Predictors of Transition to Frailty in Middle-Aged and Older People With HIV: A Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 518-527.	2.1	7
9	Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation. MBio, 2021, 12, e0278421.	4.1	19
10	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.8	15
11	Characteristics of Motor Dysfunction in Longstanding Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 71, 1532-1538.	5.8	14
12	White Matter Abnormalities Linked to Interferon, Stress Response, and Energy Metabolism Gene Expression Changes in Older HIV-Positive Patients on Antiretroviral Therapy. Molecular Neurobiology, 2020, 57, 1115-1130.	4.0	19
13	Neuroinflammation associates with antioxidant heme oxygenase-1 response throughout the brain in persons living with HIV. Journal of NeuroVirology, 2020, 26, 846-862.	2.1	6
14	Detection of misfolded protein aggregated in HIVâ€infected people. Alzheimer's and Dementia, 2020, 16, e044336.	0.8	0
15	Heme oxygenase-1 promoter (GT) <sub> <i>n</i> </sub> polymorphism associates with HIV neurocognitive impairment. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	14
16	Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580. Journal of Virology, 2020, 94, .	3.4	20
17	Lipocalin-2 mediates HIV-1 induced neuronal injury and behavioral deficits by overriding CCR5-dependent protection. Brain, Behavior, and Immunity, 2020, 89, 184-199.	4.1	19
18	Small Animal Model of Post-chemotherapy Tuberculosis Relapse in the Setting of HIV Co-infection. Frontiers in Cellular and Infection Microbiology, 2020, 10, 150.	3.9	12

#	Article	IF	CITATIONS
19	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	4.7	15
20	HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. Cell Death and Differentiation, 2019, 26, 1942-1954.	11.2	11
21	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.8	28
22	Frailty in medically complex individuals with chronic HIV. Aids, 2019, 33, 1603-1611.	2.2	20
23	BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism. Journal of Neuroscience, 2018, 38, 4288-4300.	3.6	31
24	When do models of NeuroAIDS faithfully imitate "the real thing�. Journal of NeuroVirology, 2018, 24, 146-155.	2.1	11
25	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Journal of the International Neuropsychological Society, 2018, 24, 163-175.	1.8	29
26	Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection. Journal of Neuroinflammation, 2018, 15, 70.	7.2	33
27	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.7	26
28	Measures of Physical and Mental Independence Among HIV-Positive Individuals: Impact of Substance Use Disorder. AIDS Research and Human Retroviruses, 2017, 33, 1048-1055.	1.1	2
29	Modeling brain lentiviral infections during antiretroviral therapy in AIDS. Journal of NeuroVirology, 2017, 23, 577-586.	2.1	7
30	Degradation of heme oxygenaseâ€1 by the immunoproteasome in astrocytes: A potential interferonâ€Î³â€dependent mechanism contributing to HIV neuropathogenesis. Glia, 2017, 65, 1264-1277.	4.9	23
31	HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via Î <sup>2</sup> -Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. American Journal of Pathology, 2017, 187, 91-109.	3.8	29
32	Friedreich Ataxia: Developmental Failure of the Dorsal Root Entry Zone. Journal of Neuropathology and Experimental Neurology, 2017, 76, 969-977.	1.7	43
33	Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia. Journal of Neuropathology and Experimental Neurology, 2017, 76, 665-675.	1.7	8
34	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	7.2	30
35	Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 105-113.	4.0	67
36	MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology. PLoS Pathogens, 2017, 13, e1006360.	4.7	65

#	Article	IF	CITATIONS
37	Spinal Cord Ventral Horns and Lymphoid Organ Involvement in Powassan Virus Infection in a Mouse Model. Viruses, 2016, 8, 220.	3.3	31
38	Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1. Scientific Reports, 2016, 6, 21522.	3.3	62
39	Apolipoprotein E Îμ4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. Journal of NeuroVirology, 2016, 22, 607-614.	2.1	13
40	The significance of intercalated discs in the pathogenesis of Friedreich cardiomyopathy. Journal of the Neurological Sciences, 2016, 367, 171-176.	0.6	5
41	Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. Journal of NeuroVirology, 2016, 22, 431-441.	2.1	61
42	Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. Journal of NeuroVirology, 2016, 22, 479-487.	2.1	26
43	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	4.0	31
44	Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. Journal of NeuroVirology, 2016, 22, 170-178.	2.1	112
45	Lower CSF A? is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Current HIV Research, 2016, 14, 324-330.	0.5	4
46	The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients. Aids, 2015, 29, 1483-1491.	2.2	32
47	Primary Langerhans cell histiocytosis of the lacrimal gland in an adult. Canadian Journal of Ophthalmology, 2015, 50, e40-e43.	0.7	3
48	Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1093-1118.	1.7	46
49	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clinical Infectious Diseases, 2015, 61, 1476-1484.	5.8	27
50	Reply to Haddow, et al Clinical Infectious Diseases, 2015, 60, 1442-3.	5.8	0
51	Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered. Current HIV/AIDS Reports, 2015, 12, 272-279.	3.1	130
52	Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology, 2015, 84, 241-250.	1.1	40
53	CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. Journal of NeuroVirology, 2015, 21, 559-567.	2.1	36
54	Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. Clinical Infectious Diseases, 2015, 60, 473-480.	5.8	326

#	Article	IF	CITATIONS
55	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE, 2014, 9, e103123.	2.5	29
56	Astrocyte Elevated Gene-1 Is a Novel Modulator of HIV-1-associated Neuroinflammation via Regulation of Nuclear Factor-κB Signaling and Excitatory Amino Acid Transporter-2 Repression. Journal of Biological Chemistry, 2014, 289, 19599-19612.	3.4	43
57	The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV. American Journal of Epidemiology, 2014, 180, 297-307.	3.4	35
58	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 2014, 82, 2055-2062.	1.1	255
59	Quantitative neuropathology associated with chronic manganese exposure in South African mine workers. NeuroToxicology, 2014, 45, 260-266.	3.0	38
60	HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. Journal of NeuroVirology, 2014, 20, 209-218.	2.1	27
61	Gp120 in the pathogenesis of human immunodeficiency virus–associated pain. Annals of Neurology, 2014, 75, 837-850.	5.3	76
62	Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research ( <i>CHARTER</i> ) Cohort. Journal of HIV/AIDS and Social Services, 2014, 13, 8-25.	0.7	6
63	Potential Roles of Microglial Cell Progranulin in HIV-Associated CNS Pathologies and Neurocognitive Impairment. Journal of NeuroImmune Pharmacology, 2014, 9, 117-132.	4.1	11
64	Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders. Journal of Clinical Investigation, 2014, 124, 4459-4472.	8.2	62
65	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. Journal of NeuroVirology, 2013, 19, 393-401.	2.1	38
66	Wnt Signaling in the Pathogenesis of Human HIV-Associated Pain Syndromes. Journal of NeuroImmune Pharmacology, 2013, 8, 956-964.	4.1	34
67	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. Journal of Antimicrobial Chemotherapy, 2013, 68, 684-689.	3.0	34
68	Neurovirological Correlation With HIV-Associated Neurocognitive Disorders and Encephalitis in a HAART-Era Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 487-495.	2.1	111
69	Concurrent Classification Accuracy of the HIV Dementia Scale for HIV-Associated Neurocognitive Disorders in the CHARTER Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 36-42.	2.1	24
70	Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity. Neurobehavioral HIV Medicine, 2013, 5, 11.	2.0	25
71	Chronic-Pain-Associated Astrocytic Reaction in the Spinal Cord Dorsal Horn of Human Immunodeficiency Virus-Infected Patients. Journal of Neuroscience, 2012, 32, 10833-10840.	3.6	152
72	Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2012, 56, 1985-1989.	3.2	14

#	Article	IF	CITATIONS
73	Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 376-381.	2.1	72
74	Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. Aids, 2012, 26, 2327-2335.	2.2	95
75	Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology, 2012, 433, 498-505.	2.4	11
76	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Journal of NeuroVirology, 2012, 18, 511-520.	2.1	24
77	Prefrontal Dopaminergic and Enkephalinergic Synaptic Accommodation in HIV-associated Neurocognitive Disorders and Encephalitis. Journal of NeuroImmune Pharmacology, 2012, 7, 686-700.	4.1	78
78	Substance abuse increases the risk of neuropathy in an HIVâ€infected cohort. Muscle and Nerve, 2012, 45, 471-476.	2.2	34
79	Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. Journal of NeuroVirology, 2012, 18, 81-90.	2.1	15
80	The National NeuroAIDS Tissue Consortium Brain Gene Array: Two Types of HIV-Associated Neurocognitive Impairment. PLoS ONE, 2012, 7, e46178.	2.5	150
81	Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV-Infected Persons. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 316-323.	1.8	10
82	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology, 2011, 17, 3-16.	2.1	1,327
83	Clinical factors related to brain structure in HIV: the CHARTER study. Journal of NeuroVirology, 2011, 17, 248-57.	2.1	158
84	Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. Journal of Antimicrobial Chemotherapy, 2011, 66, 354-357.	3.0	82
85	Pathology and pathogenesis of sensory neuropathy in Friedreich's ataxia. Acta Neuropathologica, 2010, 120, 97-108.	7.7	72
86	Synaptic Proteins Linked to HIV-1 Infection and Immunoproteasome Induction: Proteomic Analysis of Human Synaptosomes. Journal of NeuroImmune Pharmacology, 2010, 5, 92-102.	4.1	55
87	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. Archives of Neurology, 2010, 67, 552.	4.5	347
88	Persistent Hijacking of Brain Proteasomes in HIV-Associated Dementia. American Journal of Pathology, 2010, 176, 893-902.	3.8	49
89	Low atazanavir concentrations in cerebrospinal fluid. Aids, 2009, 23, 83-87.	2.2	112
90	Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Annals of Neurology, 2008, 64, 566-572.	5.3	147

#	Article	IF	CITATIONS
91	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Archives of Neurology, 2008, 65, 65.	4.5	777
92	The neuropathology of HIV. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 301-317.	1.8	7
93	Abnormal Striatal Dopaminergic Synapses in National NeuroAIDS Tissue Consortium Subjects with HIV Encephalitis. Journal of NeuroImmune Pharmacology, 2006, 1, 410-420.	4.1	64
94	Potential Role for White Matter Lysosome Expansion in HIV-Associated Dementia. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 422-425.	2.1	35
95	Host genetic polymorphisms in human immunodeficiency virus–related neurologic disease. Journal of NeuroVirology, 2004, 10, 67-73.	2.1	26
96	Interrater Reliability of Clinical Ratings and Neurocognitive Diagnoses in HIV. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 759-778.	1.3	284
97	Acquired neuronal channelopathies in HIV-associated dementia. Journal of Neuroimmunology, 2004, 157, 111-119.	2.3	58
98	Brain aging in acquired immunodeficiency syndrome: Increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. Journal of NeuroVirology, 2004, 10, 98-108.	2.1	62
99	Human Microglial Cell Isolation from Adult Autopsy Brain: Brain pH, Regional Variation, and Infection with Human Immunodeficiency Virus Type 1. Journal of NeuroVirology, 2003, 9, 346-357.	2.1	20
100	Neuropathological and Ultrastructural Features of Amebic Encephalitis Caused by <i>Sappinia diploidea</i> . Journal of Neuropathology and Experimental Neurology, 2003, 62, 990-998.	1.7	51
101	Amoebic Encephalitis Due to Sappinia diploidea. JAMA - Journal of the American Medical Association, 2001, 285, 2450.	7.4	93
102	Oncocytoma in Melanocytoma of the Spinal Cord: Case Report. Neurosurgery, 2000, 47, 756-759.	1.1	16
103	Incarceration and the acquired immunodeficiency syndrome: Autopsy results in Texas prison inmates. Human Pathology, 1996, 27, 1282-1287.	2.0	4
104	Quantifying Apoptosis in Banked Human Brains Using Flow Cytometry. Journal of Neuropathology and Experimental Neurology, 1996, 55, 1164-1172.	1.7	11
105	Increased vulnerability to demyelination in streptozotocin diabetic rats. , 1996, 373, 55-61.		15
106	Diffuse microgliosis associated with cerebral atrophy in the acquired immunodeficiency syndrome. Annals of Neurology, 1993, 34, 65-70.	5.3	65
107	Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome. Annals of Neurology, 1992, 32, 31-40.	5.3	54
108	Macrophage Apolipoprotein Synthesis and Endoneurial Distribution as a Response to Segmental Demyelination. Journal of Neuropathology and Experimental Neurology, 1991, 50, 383-407.	1.7	23

#	Article	IF	CITATIONS
109	Brain lipofuscin concentration and oxidant defense enzymes in leadâ€poisoned neonatal rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1979, 5, 683-698.	2.3	12
110	Neonatal lead toxicity andin vitrolipid peroxidation of rat brain. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1979, 5, 671-682.	2.3	14
111	The effect of lead on oxidative hemolysis and erythrocyte defense mechanisms in the rat. Toxicology and Applied Pharmacology, 1978, 45, 119-129.	2.8	40